https://www.biospace.com/article/releases/cerevel-therapeutics-announces-publication-in-the-lancet-of-emraclidine-data-from-phase-1b-clinical-trial-in-people-living-with-schizophrenia/
0
0
Cerevel Therapeutics Announces Publication in The Lancet of Emraclidine Data from Phase 1b Clinical Trial in People Living with Schizophrenia - BioSpace
12/16/22 at 2:48am
Organization
BioSpace
Author
BioSpace
Details
59 words
Summarize
Pharmaceuticals & Biotech Health Drugs & Medications Nasdaq The Lancet Clinical Trials People Living with Schizophrenia - BioSpace Cerevel Therapeutics emraclidine CERE neuroscience diseases M4
Cerevel Therapeutics (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, announced today the publication of data from its Phase 1b clinical trial of emraclidine, a novel muscarinic M4 selective positive…
Create an account or login to join the discussion